BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

7:03 PM
 | 
Aug 04, 2008
 |  BC Extra  |  Clinical News

Schering-Plough reports boceprevir data

Schering-Plough (NYSE:SGP) reported top-line data from the two 28-week arms in the Phase II HCV SPRINT-1 trial showing that more than half of genotype 1 HCV patients on boceprevir-based combination therapy had sustained virologic response after 24 weeks of follow...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >